Skip to main content

Table 1 Baseline clinical characteristics of placebo patients with centrally confirmed HER2+ breast cancer in TEACH

From: Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

  N (%)
All HR− HR+
( N= 1,260) ( N= 561) ( N= 699)
Median age, yrs (range) 50 (22–81) 51 (24–81) 48 (22–80)
Age range (%)    
  <40 217 (17) 78 (14) 139 (20)
  40-50 446 (36) 160 (28) 286 (41)
  50-60 414 (33) 224 (40) 190 (27)
  60-70 155 (12) 83 (15) 72 (10)
  >70 28 (2) 16 (3) 12 (2)
Postmenopausal, n (%) 854 (68) 403 (72) 451 (65)
Race, n (%)    
  White 840 (67) 370 (66) 470 (67)
  Asian 298 (23) 135 (24) 163 (23)
  Black 35 (3) 16 (3) 19 (3)
  Other/unknown 87 (7) 40 (7) 47 (7)
Median time since initial diagnosis, yrs (range) 3 (0–15) 2 (0–15) 3 (0–12)
Years since initial diagnosis, n (%)    
  ≤4 916 (73) 430 (77) 486 (70)
  >4 344 (27) 131 (23) 213 (30)
  0-1 278 (22) 138 (25) 140 (20)
Hormone receptor status, n (%)    
  HR+ (ER+ or PR+) 695 (55) - 695 (100)
  ER+ and PR+ 438 (35) - 438 (63)
  ER+ and PR- 170 (13) - 170 (24)
  ER- and PR+ 87 (7) - 87 (13)
  HR- (ER- and PR-) 561 (45) 561 (100) -
Nodal involvement, n (%) 698 (57) 303 (55) 395 (58)
Low stage (T1 N0), n (%) 220 (18) 92 (17) 128 (19)
Prior or concurrent endocrine therapy (HR+ only), n (%)    
  Yes 625 (50) - 625 (89)
  No 74 (6) - 74 (11)
  N/A 561 (45) 561 (100) -
Adjuvant chemotherapy, n (%)    
  Anthracycline without taxane 710 (56) 303 (54) 407 (58)
  Anthracycline with taxane 503 (40) 234 (42) 269 (39)
  No anthracycline 47 (4) 24 (4) 23 (3)
  1. HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy; HR+, hormone receptor positive; ER+, estrogen receptor positive; PR+, progesterone receptor positive; ER-, estrogen receptor negative; HR-, hormone receptor negative; PR-, progesterone receptor negative.